Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

C4 Therapeutics (CCCC) Equity Ratio (2019 - 2025)

C4 Therapeutics (CCCC) has 7 years of Equity Ratio data on record, last reported at 0.71 in Q4 2025.

  • For Q4 2025, Equity Ratio rose 15.66% year-over-year to 0.71; the TTM value through Dec 2025 reached 0.71, up 15.66%, while the annual FY2025 figure was 0.71, 15.66% up from the prior year.
  • Equity Ratio reached 0.71 in Q4 2025 per CCCC's latest filing, up from 0.58 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.79 in Q2 2021 and bottomed at 0.58 in Q3 2025.
  • Average Equity Ratio over 5 years is 0.67, with a median of 0.66 recorded in 2023.
  • Peak YoY movement for Equity Ratio: soared 215.37% in 2021, then decreased 12.68% in 2022.
  • A 5-year view of Equity Ratio shows it stood at 0.77 in 2021, then fell by 12.68% to 0.67 in 2022, then decreased by 2.61% to 0.65 in 2023, then dropped by 5.5% to 0.62 in 2024, then increased by 15.66% to 0.71 in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Ratio were 0.71 in Q4 2025, 0.58 in Q3 2025, and 0.59 in Q2 2025.